Drugs / Hearticellgram-AMI
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01652209 | Sep 2013 → Aug 2024 | acute myocardial infarction | Pharmicell Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07400458 | Mar 2022 → Oct 2028 expected | acute myocardial infarction | Pharmicell Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hearticellgram-AMI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01652209 ↗ |
| Modality | Cell therapy | “autologous bone marrow derived mesenchymal stem cells” NCT01652209 ↗ |
| Route | Other | “adminstered into the infarct coronary artery using balloon tipped catheter” NCT01652209 ↗ |